Long-term Follow-up of Hydrus Implant With Phacoemulsification for Lowering Eye Pressure in Glaucoma Patients

What this Trial Is About

This research investigates the long-term effectiveness and safety of the Hydrus implant combined with phacoemulsification surgery to lower intraocular pressure (IOP) in patients with glaucoma. Glaucoma patients often face high IOP, which requires ongoing control to prevent vision loss and blindness. This study aims to provide the longest follow-up data available, tracking patients for 8 to 14 years post-implantation to understand the lasting impact of the Hydrus implant on eye pressure, medication use, surgical interventions, safety, and quality of life. Participants in this study previously underwent either the combined Hydrus implant and phacoemulsification surgery, Hydrus implantation alone, or phacoemulsification alone as a control. The study collects "real world" data from up to 202 eyes treated at a center in Mainz, Germany. The focus includes evaluating IOP status over time, the need for additional IOP-lowering treatments, and safety outcomes related to these procedures. During the study, participants will have their eye pressure measured without medication washout after at least 8 years following surgery. Researchers will also assess the use of IOP-lowering medications, progression of visual field defects, and any additional surgical interventions required during follow-up. Subgroups, including those with bilateral implants, will be analyzed separately. The study's long-term observation helps provide a comprehensive view of the Hydrus implant's impact on glaucoma management over many years.

Alcon Hydrus Stent Implantation - Long Term Follow up After 8 Years